Search

ABSTRACT Erectile dysfunction is observed in about 50% of men. It has been found that diabetes mellitus increases its prevalence to 19-86.3%, necessitating attention to a therapeutic strategy. Among the available treatment methods, intracavernosal injections of mesenchymal stem cells have proven to be particularly effective. Objective The purpose of study is to assess and analyse the effectiveness of their use in the treatment of erectile dysfunction in patients with diabetes mellitus. Materials and Methods The literature search was conducted using systematic methods and analysis in databases such as Web of Science, Scopus, PubMed, Elsevier, and Springer, with 41 sources included for further review. Results The study highlights microangiopathic and neuropathic links as key factors in erectile dysfunction development in diabetic patients, stemming from endothelial dysfunction and conductivity disturbances. Mesenchymal stem cell therapy from bone marrow, adipose tissue, and umbilical cord mitigates pathogenic impact through regenerative and anti-apoptotic effects. Due to this, most studies indicate high efficacy of the treatment and rapid therapeutic action through intracavernosal administration. Some studies suggest an increase in the body’s receptor sensitivity to other drugs, such as sildenafil. Conclusion From the perspective of further research on this issue, standardising the preparation of stem cells and the treatment method using a large sample size is essential to introduce such a method as an extremely promising therapy for this delicate issue in men into practical medicine. The practical value of the study lies in the systematisation of information on different sources of mesenchymal stem cells for treating erectile dysfunction.

Genito-Pelvic Pain/Penetration Disorder is a common sexual disorder that affects an individual's sexual health and overall well-being. Education is a therapeutic resource that presents several advantages, and it can potentially generate improvements both in pain and sexual functioning-related outcomes in patients suffering from this affliction. The objective of this study was to assess if a therapeutic educational program produced improvements in the different domains of the Female Sexual Function Index in participants suffering from Genito-Pelvic Pain Penetration Disorder. Participants were randomized into a group that received a face-to-face therapeutic educational program, a group that received the same program but online, or a control group. The Female Sexual Function Index was assessed, and analysis of the change in the domains for every group was performed using multiple t-tests. Improvements were found in the face-to-face intervention group, but only the "Pain" domain showed significant improvements (−1.1 points, p < 0.05). Improvements were also found in the online group, but they were only significant in the "Pain" and "Satisfaction" domains (−0.8 points, p < 0.05 for both). A therapeutic educational program improves pain-related outcomes, and it shows a positive tendency to also improve sexual functioning-related outcomes in patients suffering from Genito-Pelvic Pain/Penetration Disorder. Registration: Clinical Trials (NCT05114473). Therapeutic education interventions are effective when treating pain associated with sexual activity, and show positive results involving other aspects of sexuality. [ABSTRACT FROM AUTHOR]

Objectives: To identify factors associated with female sexual dysfunction (FSD) among Hong Kong Chinese women in a gynaecology outpatient clinic. Methods: Chinese women aged 18 to 65 years who had been sexually active in the past 4 weeks before recruitment and attended the gynaecology clinic of Kwong Wah Hospital between October 2020 and July 2021 were invited to participate in a sexual health survey. Participant demographics were collected through the clinical management system. Sexual function in the previous 4 weeks was assessed using the Female Sexual Function Index (FSFI). Results: 206 women (mean age, 43.6 years) were included in the analysis. The mean total FSFI score was 23.44; 42% of participants were at risk of FSD, with a total FSFI score of =23.45. The score was lowest in the sexual desire domain (2.88) and highest in the coital pain domain (4.51). Participants were divided into three age groups based on their reproductive age status: 18 to 35 years (n=44), 36 to 50 years (n=116), and 51 to 65 years (n=46). Although older age groups tended to have higher risks of FSD, the differences between groups were not significant. Specifically, only the satisfaction domain score was lower in the age group of 36 to 50 years than in the age group of 18 to 35 years (4.16 vs 4.61, p=0.01). The coital pain domain score was lower in menopausal women than in premenopausal women (3.76 vs 4.51, p=0.03). Parous women had a lower sexual desire domain score (2.78 vs 3.04, p=0.04) and higher vaginal lubrication domain score (4.42 vs 3.74, p=0.02) than nulliparous women. Women using contraception had a higher vaginal lubrication domain score than women not using contraception (4.47 vs 3.91, p=0.02). Women with distress related to sexual function had a lower total FSFI score (19.74 vs 23.78, p=0.01), lower satisfaction domain score (3.80 vs 4.42, p=0.02), and lower coital pain domain score (3.38 vs 4.51, p=0.01), compared with women without distress related to sexual function. Conclusion: Although older women tend to be at higher risk of FSD, the correlation between age and FSFI score was not significant. Menopausal women had a lower coital pain domain score; women not using contraception had a lower vaginal lubrication domain score. [ABSTRACT FROM AUTHOR]

N/a.